New Treatment for Alzheimer’s

The FDA approved Aduhelm in 2021 under accelerated approval. First approved June 7, 2021. A subsequent, poorly-explained controversy eventually resulted in MEDICARE to withdraw coverage for the drug. The company decided to support patients, and as of today, has active participation to help individual patients to obtain the treatment via a company support program.

As a result of Medicare not paying for the treatment, many providers stopped administering the drug in their office. Our office had difficulty finding a provider who would administer the drug intravenously.

After some thinking and brainstorming with my staff, I decided to start this I.V. service in our office at 100 US Hwy. 1, Suite 120, Vero Beach.

We are a cash-based practice and do not accept insurance. This is because of the prohibitive overhead billing from the insurance companies. So, we make it the patient’s responsibility to obtain the Aduhelm. We assist in this process, and Biogen has a PATH Enrollment (Patient Assistance Program) for financial assistance. The intravenous medications arrive in our office ready to go. We do charge for our expenses and for the services we render. We think our pricing is more than reasonable. My goal as a physician is to help patients who so desire to get access to the first rational therapy for Alzheimer’s disease.